<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3250618/" ref="ordinalpos=5057&amp;ncbi_uid=3751890&amp;link_uid=PMC3250618" image-link="/pmc/articles/PMC3250618/figure/Fig6/" class="imagepopup">Fig. 6.  From: Smad phosphoisoform signals in acute and chronic liver injury: similarities and differences between epithelial and mesenchymal cells. </a></div><br /><div class="p4l_captionBody">Reversible shifting of hepatocytic Smad3-dependent signaling between tumor-suppression and carcinogenesis. During the carcinogenic process in human chronic liver diseases, chronic inflammation drives carcinogenesis via a shift from the pSmad3C to the pSmad3L pathway. Linker phosphorylation of Smad3 indirectly prevents Smad3C phosphorylation, pSmad3C-mediated transcription, and the cytostatic effect of TGF-Î²/activin upon hepatocytes. Inhibition of JNK activity abolishes pSmad3L-mediated oncogenic signaling, while restoring the lost tumor-suppressive pSmad3C signaling observed in normal hepatocytes</div></div>